Laura Corvatta

2.0k total citations
67 papers, 1.2k citations indexed

About

Laura Corvatta is a scholar working on Hematology, Molecular Biology and Oncology. According to data from OpenAlex, Laura Corvatta has authored 67 papers receiving a total of 1.2k indexed citations (citations by other indexed papers that have themselves been cited), including 52 papers in Hematology, 46 papers in Molecular Biology and 44 papers in Oncology. Recurrent topics in Laura Corvatta's work include Multiple Myeloma Research and Treatments (48 papers), Protein Degradation and Inhibitors (37 papers) and Peptidase Inhibition and Analysis (23 papers). Laura Corvatta is often cited by papers focused on Multiple Myeloma Research and Treatments (48 papers), Protein Degradation and Inhibitors (37 papers) and Peptidase Inhibition and Analysis (23 papers). Laura Corvatta collaborates with scholars based in Italy, Poland and Brazil. Laura Corvatta's co-authors include Massimo Offidani, Attilio Olivieri, Pietro Leoni, Corrado Girmenia, Livio Pagano, Silvia Gentili, A. Del Favero, Marino Brunori, Mauro Montanari and Anna Mele and has published in prestigious journals such as SHILAP Revista de lepidopterología, Blood and Cancer.

In The Last Decade

Laura Corvatta

65 papers receiving 1.2k citations

Peers

Laura Corvatta

HEMAT

ONCOL

EPIDE

Akiko Hori Japan

Anne Vekhoff France

Steve Schey United Kingdom

Stéphane Vigouroux France

Brian C. Shaffer United States

C Ferry France

Marcus Gorschlüter Germany

Haitao Meng China

María Ortiz Spain

Karin Bilger France

Akiko Hori Japan

Laura Corvatta

302 ×0.5

HEMAT

294 ×0.6

ONCOL

284 ×0.6

288 ×0.9

EPIDE

228 ×0.7

Citations per year, relative to Laura Corvatta Laura Corvatta (= 1×) peers Akiko Hori

Countries citing papers authored by Laura Corvatta

Since Specialization

Citations

This map shows the geographic impact of Laura Corvatta's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Laura Corvatta with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Laura Corvatta more than expected).

Fields of papers citing papers by Laura Corvatta

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Laura Corvatta. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Laura Corvatta. The network helps show where Laura Corvatta may publish in the future.

Co-authorship network of co-authors of Laura Corvatta

This figure shows the co-authorship network connecting the top 25 collaborators of Laura Corvatta. A scholar is included among the top collaborators of Laura Corvatta based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Laura Corvatta. Laura Corvatta is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Gatti, Arianna, Bruno Brando, Lorenzo Brunetti, et al.. (2024). Breast Cancer With Release of Tumor Cells in Peripheral Blood Mimicking Acute Myeloid Leukemia. Journal of Hematology. 13(4). 168–173. 1 indexed citations

Fazio, Francesca, Maria Teresa Petrucci, Laura Corvatta, et al.. (2024). Belantamab mafodotin in triple‐refractory multiple myeloma patients: A retro‐prospective observational study in Italy. SHILAP Revista de lepidopterología. 5(3). 485–493. 1 indexed citations

Corvatta, Laura, et al.. (2023). Current Main Topics in Multiple Myeloma. Cancers. 15(8). 2203–2203. 4 indexed citations

Corvatta, Laura, et al.. (2023). Novel Immunotherapies and Combinations: The Future Landscape of Multiple Myeloma Treatment. Pharmaceuticals. 16(11). 1628–1628. 11 indexed citations

Offidani, Massimo, et al.. (2021). Novel Experimental Drugs for Treatment of Multiple Myeloma. Journal of Experimental Pharmacology. Volume 13. 245–264. 23 indexed citations

Gentile, Massimo, Massimo Offidani, Ernesto Vigna, et al.. (2015). Ixazomib for the treatment of multiple myeloma. Expert Opinion on Investigational Drugs. 24(9). 1287–1298. 41 indexed citations

Gentile, Massimo, Massimo Offidani, Ernesto Vigna, et al.. (2015). Smoldering multiple myeloma: to treat or not to treat. Expert Opinion on Pharmacotherapy. 16(6). 785–790. 4 indexed citations

Offidani, Massimo, et al.. (2014). An evidence-based review of ixazomib citrate and its potential in the treatment of newly diagnosed multiple myeloma. OncoTargets and Therapy. 7. 1793–1793. 45 indexed citations

Offidani, Massimo, Pietro Leoni, Laura Corvatta, et al.. (2010). ThaDD plus high dose therapy and autologous stem cell transplantation does not appear superior to ThaDD plus maintenance in elderly patients with de novo multiple myeloma. European Journal Of Haematology. 84(6). 474–483. 12 indexed citations

10.

Offidani, Massimo, Pietro Leoni, Laura Corvatta, et al.. (2010). Outcome and Toxicity in the Modern Era of New Drugs for Multiple Myeloma: A Reappraisal for Comparison With Future Investigational Trials. Clinical Lymphoma Myeloma & Leukemia. 10(5). 353–360. 2 indexed citations

11.

Offidani, Massimo, Laura Corvatta, Lara Malerba, Marco Marconi, & Pietro Leoni. (2004). Infectious Complications in Adult Acute Lymphoblastic Leukemia (ALL): Experience at One Single Center. Leukemia & lymphoma. 45(8). 1617–1621. 11 indexed citations

12.

Fianchi, Luana, Marco Picardi, Laura Cudillo, et al.. (2004). Aspergillus niger infection in patients with haematological diseases: a report of eight cases. Mycoses. 47(3-4). 163–167. 20 indexed citations

13.

Offidani, Massimo, Laura Corvatta, Attilio Olivieri, et al.. (2004). Thalidomide plus oral melphalan compared with thalidomide alone for advanced multiple myeloma. The Hematology Journal. 5(4). 312–317. 21 indexed citations

14.

Offidani, Massimo, Laura Corvatta, Lara Malerba, et al.. (2004). Comparison of two regimens for the treatment of elderly patients with acute lymphoblastic leukaemia (ALL). Leukemia & lymphoma. 46(2). 233–238. 13 indexed citations

15.

Offidani, Massimo, Laura Corvatta, Lara Malerba, et al.. (2004). Risk assessment of patients with hematologic malignancies who develop fever accompanied by pulmonary infiltrates. Cancer. 101(3). 567–577. 10 indexed citations

16.

Offidani, Massimo, Laura Corvatta, Riccardo Centurioni, et al.. (2003). High-dose daunorubicin as liposomal compound (Daunoxome®) in elderly patients with acute lymphoblastic leukemia1. The Hematology Journal. 4(1). 47–53. 18 indexed citations

17.

Offidani, Massimo, Anna Mele, Laura Corvatta, et al.. (2002). Gemcitabine Alone or Combined with Cisplatin in Relapsed or Refractory Multiple Myeloma. Leukemia & lymphoma. 43(6). 1273–1280. 10 indexed citations

18.

Girmenia, Corrado, et al.. (2000). The epidemiology of fusariosis in patients with haematological diseases. British Journal of Haematology. 111(1). 272–276. 55 indexed citations

19.

Offidani, Massimo, Laura Corvatta, Attilio Olivieri, et al.. (1999). Infectious complications after autologous peripheral blood progenitor cell transplantation followed by G-CSF. Bone Marrow Transplantation. 24(10). 1079–1087. 53 indexed citations

20.

Olivieri, Attilio, Antonella Poloni, Mauro Montanari, et al.. (1997). Pharmacologic Bone Marrow Purging: Is There Any Place for Etoposide? In Vitro Comparison with Mafosfamide. Journal of Hematotherapy. 6(2). 137–144. 5 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact